122TiPGeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. (13th May 2019) - Loibl, S; Jackisch, C; Rastogi, P; Seiler, S; Lucas, P C; Denkert, C; Costantino, J; Nekljudova, V; Wolmark, N; Geyer, C